- Original article
- Open Access
Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom
© The Author(s) 2017
Received: 21 November 2016
Accepted: 17 February 2017
Published: 17 April 2017
To evaluate the characteristics and racial variations amongst patients with polypoidal choroidal vasculopathy (PCV) in the United States and the United Kingdom.
Fundus photos and indocyanine green angiography images were evaluated in a multicenter retrospective study to establish the diagnosis of PCV. Visual acuity (VA) was recorded in ETDRS letter count.
Eighty eyes of 71 PCV patients (average age of 69.4 ± 10.4 years) were included in the analysis. Of the total 71 subjects, 46 (65%) were women, 33 (46.5%) were Blacks, 16 (22.5%) were Whites, 19 (26.8%) were Asians and 3 (4.2%) belonged to other races. The Black subgroup had vision gain of 3.5 letters. The White and Asian subgroups had vision loss of 13.1 and 3.5 letters, respectively. There was female predominance in Blacks (67%), Whites (69%), and Asians (58%). PCV was found to be a bilateral disease in 14 patients (20%). There was significant decrease of 7 letters with every decade increase in age (p = 0.005). Final VA was worse in males when compared to females (p = 0.042), and worse in Whites when compared to Blacks (p = 0.005). For every 10 letters worse in initial VA upon diagnosis with PCV, the final VA was worse by 6 letters (p < 0.001). The location of the polypoidal lesion within the macula was associated with significant decrease of 14 letters in BCVA (p = 0.02). The length of follow up was significantly associated with worse visual outcome (p = 0.012). Final VA had no significant correlation with the lens status, or the different treatment modalities.
Based on our cohort from tertiary centers in the United States and United Kingdom, PCV is a bilateral disease in one-fifth of patients. It features a variable female predominance based on ethnicity. Increased age, worse vision upon initial presentation, longer follow up and macular location of the polyp were associated with worse visual outcome.
Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity that is associated with abnormal inner choroidal vascular network of vessels ending in an aneurysmal projection, visible clinically in some cases as orange reddish spheroid polyp-like structures . PCV is characterized by multiple, recurrent, serosanguinous detachments of the retinal pigment epithelium and neurosensory retina secondary to leakage and bleeding from the polypoidal lesions [1, 2].
Most of the large PCV studies come from Japan, South Korea and Singapore, where the disease has been reported to be more prevalent. Japanese studies have shown that one-fourth to one half of the elderly patients with neovascular age-related macular degeneration (AMD) in Japan were diagnosed with PCV [3, 4]. However, individuals of other ethnicities may develop PCV as well. Lafaut et al.  reported ICGA-confirmed PCV in 4% of white patients with occult choroidal neovascularization. Recently, a Swiss study revealed PCV in 16.8% of Caucasian patients with neovascular AMD .
Indocyanine green angiography (ICGA) remains the gold standard in establishing the diagnosis of PCV, because it can demonstrate the polypoidal lesions and the branching vascular network underneath the RPE, which can be missed using standard fluorescein angiography . However, it is important to realize that not all focal subretinal nodular hyperfluorescence on ICGA is presumed to be due to polyps. Therefore, the EVEREST study report 2 described the imaging and grading protocols to standardize the diagnostic criteria for future randomized controlled trials on PCV . Multiple reports have described the optical coherence tomography (OCT) features of PCV and correlated them with ICGA findings [9–17].
The natural course of PCV usually follows a relapsing-remitting course, where the visual outcome can vary. Uyama et al.  followed 14 eyes of 12 patients with PCV for 2 years without any treatment. A favorable outcome was noted in 50% of patients, whereas the remaining half suffered from persistence of the disease and repeated serosanguinous leakage, resulting in unfavorable visual outcome. On the other hand, the treatment guidelines for PCV were established by the Everest Study Group (a prospective multicenter randomized controlled clinical trial, which included 61 Asian patients) which recommended treatment of juxtafoveal and subfoveal PCV with ICGA-guided photodynamic therapy (PDT) or PDT plus 3 ranibizumab intravitreal injections 1 month apart [19, 20]. Recent studies have observed and reported resistance to ranibizumab in some patients with PCV [21, 22]. There have been recent studies from Japan reporting the use of aflibercept in PCV patients, who are naïve to treatment or not responding to ranibizumab [23–25]. The long term behavior of visual acuity (VA) in PCV patients of different ethnicities remains controversial and further studies are warranted. Our study describes the characteristics and visual outcomes in PCV patients of different ethnicities from three tertiary centers in the United States and the United Kingdom.
We retrospectively reviewed the records of patients with PCV at Yale Eye Center, Moorfields Eye Hospital and New England Eye Center between September 2005 and December 2015. Study protocols were approved by the Institutional Review Board at Yale University and Tufts University and were in accordance with the Health Insurance Portability and Accountability Act. The research adhered to the tenets of the Declaration of Helsinki for research involving human subjects.
After comprehensive chart review, 155 eyes with PCV were identified in a retrospective multicenter study. The VA score from the United Kingdom (Moorfields) was recorded using the Early Treatment Diabetic Retinopathy Study (ETDRS) letter count. The VA score from the United States centers (Tufts University and Yale University) was recorded using Snellen charts, then converted to ETDRS letter count using a conversion chart. The VA for all patients was documented at baseline and last follow up visit. Age at the time of initial diagnosis, ethnicity, and lens status (phakic versus pseudophakic) were documented. Dilated fundus examination findings and color fundus photography images were reviewed. Patients with concurrent retinal pathologies were excluded from the analysis.
History of previous treatments with focal laser, PDT, intravitreal injections with anti-VEGF agents (bevacizumab, ranibizumab and aflibercept) were quantified and recorded in a chronological order.
Morphological features of PCV were identified by 2 independent authors (TA and NM) using a standard protocol to analyze color photographs, ICGA and OCT images. Disagreement between the two observers was resolved by open adjudication.
The variables data are presented as mean ± standard deviation. Multivariate analysis model was performed to determine the effects of age, gender, ethnicity, BCVA upon initial presentation, length of follow up, and different treatment modalities on the final BCVA in patients with PCV. p values of <0.05 were considered statistically significant.
Demographics of subjects with polypoidal choroidal vasculopathy included in the analysis
Number of subjects
80 eyes (71 patients)
Mean age (years)
69.4 ± 10.4
Follow up (months)
31.8 ± 27.9
Last follow up
65.1 ± 19.1
63.0 ± 27.6
Mean change in BCVA
−2.1 ± 24.2 (ETDRS Letters)
25 males (35%)
46 females (65%)
66 phakic eyes (82.5%)
14 pseudophakic eyes (17.5%)
Number of subjects
Mean change in BCVA
−2.3 ± 29.0
3.5 ± 18.2
−13.1 ± 26.9
2.3 ± 10
Mean age (years)
67.8 ± 9.2
71.1 ± 9.8
67.8 ± 13.3
67.7 ± 6.8
Location of the polypoidal lesions
Location and laterality of polypoidal lesions on indocyanine green angiography of eyes with polypoidal choroidal vasculopathy included in the analysis
Number of eyes
Location of polyps
Number of subjects
Optical coherence tomography imaging
Seventy-five eyes out of the total 80 eyes had OCT images that were available for analysis. Sixty-six eyes had either time-domain or spectral-domain OCT imaging, 7 eyes had prototype swept source OCT imaging and 2 eyes had AngioVue OCT angiography (Optovue, Inc, Fremont, CA). Out of the 75 eyes that had OCT imaging, 71 eyes had PED, 29 eyes had BVN, 65 eyes had SRF, and 18 eyes had IRF.
Bilateral polypoidal choroidal vasculopathy
Based on ICGA findings in our study, and applying the abovementioned EVEREST study definitions, PCV was found to be a bilateral disease in 14/71 patients (20%). Out of the remaining 57 subjects with presumed unilateral PCV, one Asian patient had her fellow eye enucleated after a non-traumatic massive retinal hemorrhage, and another Asian patient had no light perception in her fellow eye (phthisis bulbi after untreated chronic hemorrhagic retinal detachment). Bilateral PCV was noted in 7/33 Black subjects (21%), 3/16 White subjects (19%) and 4/19 Asian subjects (21%). Table 2 summarizes these findings.
Number of eyes
Observation (no treatment)
Intravitreal injections with anti-VEGF agents
Total number of anti-VEGF injections
Intravitreal injection with triamcinolone
Pars plana vitrectomy
Multiple linear regression of demographic and clinical variables: effect on best corrected visual acuity at last follow up in patients with polypoidal choroidal vasculopathy
The term PCV was first coined by Yannuzzi in 1982 (Yannuzzi LA. Idiopathic Polypoidal Choroidal Vasculopathy. Presented at the Macula Society Meeting in Miami, Florida). The features of PCV were later described in 1990 . Kleiner and associates used the terminology “posterior uveal bleeding syndrome” to describe PCV . Further understanding of this peculiar entity has matured over the past three decades. Yannuzzi and colleagues diagnosed PCV in 7.8% of 167 consecutive patients with presumed neovascularized AMD in the United States . Recently, Kuroda et al.  reported PCV in 52.5% of 343 eyes with neovascular AMD in Japan. Our retrospective multicenter study investigated the characteristics and racial variations of PCV patients in three tertiary centers the United States and the United Kingdom, and evaluated the predictive factors that determine visual outcomes in those patients.
PCV involvement was reported to be mostly unilateral (90% of patients) in a large Japanese cohort of 100 patients with PCV . Recently, Alasil et al.  demonstrated choroidal vascular abnormalities in the unaffected eyes of patients with PCV using en face prototype swept source OCT. In our cohort, PCV was found to be bilateral in about 20% of patients regardless of the ethnic subgroup. PCV is usually diagnosed in patients between the ages of 50 and 65 years old. The average age of onset reported in the literature for PCV patients was 60 years . White patients tend to present with PCV at an older age . The mean age in our cohort was 69 years old, which can be explained by the different ethnicities included in the sample, including 22.5% white individuals. Final VA was decreased by seven ETDRS letters for every decade increase in age starting at 50 years.
Male preponderance was reported in multiple Asian PCV studies, including 63% of 100 Japanese patients,  78.5% of 79 Korean patients,  and 68.4% of 19 Chinese patients . On the other hand, the initial posterior uveal bleeding syndrome report described predominance in women over men in a small sample of black patients . de Mello et al. reported female preponderance (67% of 72 Brazilian patients) . Hatz et al.  reported female preponderance (71% of 34 of Caucasian Swiss patients with PCV). Davis et al.  reported female preponderance of 52% in 27 white patients with PCV in the United States. In our cohort, PCV featured a variable female predominance based on ethnicity (58% in Asians, 67% in Blacks and 69% in Whites). Our multivariate analysis suggested that final VA could be worse in males when compared to females in PCV. However, the p value of 0.042, the small sample size and the 2:1 female to male ratio make those gender-related conclusions uncertain.
A panel of PCV experts analyzed the body of literature on PCV together with results of the Everest trial, and made recommendations for the management of PCV which were based on this analysis and expert opinions . Delivering PDT to the polypoidal lesions will result in occlusion of the polypoidal lesions and focal choroidal ischemia at the treated areas [35, 36], which may result in further VEGF secretion from the surrounding intact branching vascular network and subsequent recurrence of serosanguinous exudation causing further visual deterioration. Hence, the benefits of combining PDT with intravitreal injections of anti-VEGF agents were strongly emphasized . Focal laser can be utilized to target polypoidal lesions outside the central macula. However, it may cause progressive photoreceptor degeneration with fibrosis and atrophic changes in the area over the scar, resulting in no improvement or even worsening of VA. Our multivariate analysis showed no significant effects of different treatment modalities on BCVA, probably because our sample was mixed in regards to the treatments delivered to the patients, and our retrospective study was not designed to examine the effects of different treatment modalities on visual outcomes in patients with PCV. As expected, the location of the polypoidal lesion within the anatomic macula was associated with worse visual outcome.
Final VA was significantly worse (by 16 letters) in Whites when compared to Blacks, but was not statistically different when Asians were compared to Blacks. Blacks were used as the reference group, because they were the largest ethnic subgroup in our cohort. This might very well be a random finding despite the p value, given the relatively small sample size, the Black group had twice as much extra-macular lesions compared with the White group, which could explain the visual outcome differences. Nevertheless, PCV appears to have two forms: a subset of choroidal neovascularization from a variety of etiologies, most commonly related to neovascular age-related macular degeneration (AMD); or a different disease from AMD which is usually encountered in darkly pigmented individuals, and without other characteristic fundus findings of AMD. However, there appears to be some overlapping features between these two entities.
The baseline BCVA upon initial diagnosis with PCV and the length of follow up were both found to be important predictors of final VA. Traditionally, patients with active or poorly responding PCV lesions tend to follow longer than patients who respond well to treatment. The mean follow up for the patients in our cohort was 32 months, and the range varied between 2 and 120 months. The relapsing-remitting nature of PCV may explain the lengthy follow up in some of our patients.
Our study has a number of strengths; in particular, the ICGA-confirmed PCV patients included in this study met the EVEREST inclusion criteria, were diverse and probably representative of subjects with PCV seen in the United Kingdom and United States. The sample size was relatively small compared to the studies from Japan, South Korea and Singapore. However, different ethnicities were represented including Black, Asian and White individuals.
Our study also has a number of limitations related to its retrospective nature. There was variability in the follow up duration between patients. The centers participating in the study were tertiary referral centers. Our multivariate analysis r-squared result of 0.55 suggests that the model doesn’t explain well the observed data. The study was not specifically designed to evaluate the effects of ethnicity and different treatment modalities on the visual outcome in patients with PCV.
OCT angiography (OCTA) is a non-invasive imaging technology that can visualize the retinal and choroidal vasculature. This technology is increasingly being used to image CNV since it can visualize the neovascular complex both above and beneath the RPE [37, 38]. Figure 2 shows an example of OCTA imaging of polypoidal lesions and branching vascular network in PCV. Previous studies have shown that the branching vascular network can regularly be detected using OCTA [39, 40]. However, Kim et al.  showed that only 50% of the polyps could be identified using this imaging modality. It’s been hypothesized that a turbulent flow inside the polyp would not generate a decorrelation signal inside the threshold range of commercially available OCTA . Therefore, we anticipate ICGA to remain the gold standard for making the diagnosis of PCV and guiding the PDT treatment when indicated. In the future, the speed and resolution improvements in OCT angiography might provide an additional diagnostic and monitoring tool in PCV.
Based on our cohort from tertiary centers in the United States and United Kingdom, PCV is a bilateral disease in 20% of patients. It features a variable female predominance based on ethnicity. The following co-variables are significantly associated with worse VA outcomes: increased age, worse vision upon initial presentation, longer follow up and macular location of the polyp.
Design of the study (TA, PAK, PAC, NKW, JSD, RAA); conduct of the study (TA, NM, PAK, AT, PAC, EN, Td, CRB, NKW, JSD, RAA); collection of data (TA, NM, PAK, PAC, EN, Td, CRB, NKW, JSD, RAA); management (TA, PAK, PAC, CRB, NKW, JSD, RAA); analysis (TA, NM, PAK, AT, PAC, EN, Td, CRB, NKW, JSD, RAA); interpretation of the data (TA, PAK, AT, PAC, CRB., NKW, JSD, RAA); preparation (TA, PAK, PAC, EN, CRB, NKW, JSD, RAA.); review (TA, NM, PAK, AT, PAC, EN, Td, CRB, NKW, JSD, RAA); and approval of the manuscript (TA, NM, PAK, AT, PAC, EN, Td, CRB, NKW, JSD, RAA). All authors read and approved the final manuscript.
Dr. Jay S. Duker is a consultant for and receives research support from Carl Zeiss Meditech, Inc. All other authors have no financial interests to disclose.
Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.
Consent for publication
The material submitted in this manuscript has not been published nor submitted simultaneously for publication elsewhere. All authors consent to that. Consents for publication of figures and ophthalmic images were obtained from the patients.
Ethics approval and consent to participate
Retrospective review of the records of patients with PCV at Yale Eye Center, Moorfields Eye Hospital and New England Eye Center between September 2005 and December 2015. Study protocols were approved by the Institutional Review Board at Yale University and Tufts University and were in accordance with the Health Insurance Portability and Accountability Act. The research adhered to the tenets of the Declaration of Helsinki for research involving human subjects. Since it was a retrospective study, there was no need for consent to participate.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1–8.View ArticlePubMedGoogle Scholar
- Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49(1):25–37.View ArticlePubMedGoogle Scholar
- Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121(10):1392–6.View ArticlePubMedGoogle Scholar
- Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144(1):15–22.View ArticlePubMedGoogle Scholar
- Lafaut BA, Leys AM, Snyers B, Rasquin F, De Laey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol. 2000;238(9):752–9.View ArticlePubMedGoogle Scholar
- Hatz K, Prunte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014;98(2):188–94.View ArticlePubMedGoogle Scholar
- Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15(2):100–10.View ArticlePubMedGoogle Scholar
- Tan CS, Ngo WK, Chen JP, Tan NW, Lim TH. EVEREST Study Group. EVEREST Study report 2: imaging grading protocol and baseline characteristics of a randomized controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99(5):624–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Alasil T, Ferrara D, Adhi M, et al. En face imaging of the choroid in polypoidal choroidal vasculopathy using swept-source optical coherence tomography. Am J Ophthalmol. 2015;159(4):634–43.View ArticlePubMedGoogle Scholar
- Kim JH, Kang SW, Kim TH, Sim SJ, Ahn J. Structure of polypoidal choroidal vasculopathy studied by colocalization between tomographic and angiographic lesions. Am J Ophthalmol. 2013;156(5):974–80.View ArticlePubMedGoogle Scholar
- Ueno C, Gomi F, Sawa M, Nishida K. Correlation of indocyanine green angiography and optical coherence tomography findings after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Retina. 2012;32(10):2006–13.View ArticlePubMedGoogle Scholar
- Ojima Y, Hangai M, Sakamoto A, et al. Improved visualization of polypoidal choroidal vasculopathy lesions using spectral-domain optical coherence tomography. Retina. 2009;29(1):52–9.View ArticlePubMedGoogle Scholar
- Rosen RB, Hathaway M, Rogers J, et al. Simultaneous OCT/SLO/ICG imaging. Invest Ophthalmol Vis Sci. 2009;50(2):851–60.View ArticlePubMedGoogle Scholar
- Kameda T, Tsujikawa A, Otani A, et al. Polypoidal choroidal vasculopathy examined with en face optical coherence tomography. Clin Exp Ophthalmol. 2007;35(7):596–601.View ArticlePubMedGoogle Scholar
- Saito M, Iida T, Nagayama D. Cross-sectional and en face optical coherence tomographic features of polypoidal choroidal vasculopathy. Retina. 2008;28(3):459–64.View ArticlePubMedGoogle Scholar
- Hong YJ, Miura M, Makita S, et al. Noninvasive investigation of deep vascular pathologies of exudative macular diseases by high-penetration optical coherence angiography. Invest Ophthalmol Vis Sci. 2013;54(5):3621–31.View ArticlePubMedGoogle Scholar
- Liu R, Li J, Li Z, et al. Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography. Retina. 2016;36(4):778–86.View ArticlePubMedGoogle Scholar
- Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133(5):639–48.View ArticlePubMedGoogle Scholar
- Koh AH, Lee WK, Chen LJ, et al. EVEREST Study: efficacy and safety of PDT in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular PCV. Retina. 2012;32(8):1453–64.View ArticlePubMedGoogle Scholar
- Koh AH, Expert PCV Panel, Chen LJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33(4):686–716.View ArticlePubMedGoogle Scholar
- Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol. 2010;150(5):666–73.View ArticlePubMedGoogle Scholar
- Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009;148(1):70–8.View ArticlePubMedGoogle Scholar
- Kawashima Y, Oishi A, Tsujikawa A, et al. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(9):1471–7.View ArticlePubMedGoogle Scholar
- Yamashita M, Nishi T, Hasegawa T, Ogata N. Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab. Clin Ophthalmol. 2014;8:343–6.PubMedPubMed CentralGoogle Scholar
- Miura M, Iwasaki T, Goto H. Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol. 2013;7:1591–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheung CM, Laude A, Wong W, et al. Improved specificity of polypoidal choroidal vasculopathy diagnosis using a modified EVEREST criteria. Retina. 2015;35(7):1375–80.View ArticlePubMedGoogle Scholar
- Tan CS, Ngo WK, Lim LW, Tan NW, Lim TH, EVEREST Study Group. EVEREST Study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study. Graefes Arch Clin Exp Ophthalmol. 2016;254(10):1923–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Kleiner RC, Brucker AJ, Johnston RL. The posterior uveal bleeding syndrome. Retina. 1990;10(1):9–17.View ArticlePubMedGoogle Scholar
- Yannuzzi LA, Wong DW, Sforzolini BS, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117(11):1503–10.View ArticlePubMedGoogle Scholar
- Kuroda Y, Yamashiro K, Miyake M, et al. Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment. Ophthalmology. 2015;122(11):2303–10.View ArticlePubMedGoogle Scholar
- Byeon SH, Lee SC, Oh HS, Kim SS, Koh HJ, Kwon OW. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol. 2008;52(1):57–62.View ArticlePubMedGoogle Scholar
- Kwok AK, Lai TY, Chan CW, Neoh EL, Lam DS. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol. 2002;86(8):892–7.View ArticlePubMedPubMed CentralGoogle Scholar
- de Mello PC, Brasil OF, Maia HS, Kaiser PK, Pereira MB, de Moraes HV Jr. Prevalence and epidemiologic features of polypoidal choroidal vasculopathy in southeastern Brazil. Eye (London). 2007;21(9):1247.View ArticleGoogle Scholar
- Davis SJ, Lauer AK, Flaxel CJ. Polypoidal choroidal vasculopathy in white patients. Retina. 2014;34(11):2185–91.View ArticlePubMedGoogle Scholar
- Mataix J, Desco MC, Palacios E, Garcia-Pous M, Navea A. Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical anaylsis of a long term study. Ophthalmic Surg Lasers Imaging. 2009;40(3):277–84.View ArticlePubMedGoogle Scholar
- Hirami Y, Tsujikawa A, Otani A, et al. Hemorrhagic complications after photodynamic therapy of polypoidal choroidal vasculopathy. Retina. 2007;27(3):335–41.View ArticlePubMedGoogle Scholar
- Jia Y, Bailey ST, Wilson DJ, et al. Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2014;121(7):1435–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Kuehlewein L, Bansal M, Lenis TL, et al. Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration. Am J Ophthalmol. 2015;160(4):739–48.View ArticlePubMedGoogle Scholar
- Kim JY, Kwon OW, Oh HS, Kim SH, You YS. Optical coherence tomography angiography in patients with polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1505–10.View ArticlePubMedGoogle Scholar
- Srour M, Querques G, Semoun O, et al. Optical coherence tomography angiography characteristics of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2016. doi:10.1136/bjophthalmol-2015-307892.Google Scholar